BR112022021179A2 - Sistema de liberação de fármaco para a liberação local de agentes terapêuticos e usos do mesmo - Google Patents
Sistema de liberação de fármaco para a liberação local de agentes terapêuticos e usos do mesmoInfo
- Publication number
- BR112022021179A2 BR112022021179A2 BR112022021179A BR112022021179A BR112022021179A2 BR 112022021179 A2 BR112022021179 A2 BR 112022021179A2 BR 112022021179 A BR112022021179 A BR 112022021179A BR 112022021179 A BR112022021179 A BR 112022021179A BR 112022021179 A2 BR112022021179 A2 BR 112022021179A2
- Authority
- BR
- Brazil
- Prior art keywords
- therapeutic agents
- drug delivery
- delivery system
- local
- local delivery
- Prior art date
Links
- 238000012377 drug delivery Methods 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 3
- 229940124597 therapeutic agent Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020102115 | 2020-07-15 | ||
| PCT/CN2021/105899 WO2022012492A1 (en) | 2020-07-15 | 2021-07-13 | Drug delivery system for locally delivering therapeutic agents and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022021179A2 true BR112022021179A2 (pt) | 2023-02-23 |
Family
ID=79555042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022021179A BR112022021179A2 (pt) | 2020-07-15 | 2021-07-13 | Sistema de liberação de fármaco para a liberação local de agentes terapêuticos e usos do mesmo |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230256106A1 (https=) |
| EP (1) | EP4181963A4 (https=) |
| JP (1) | JP2023533679A (https=) |
| KR (1) | KR20230040957A (https=) |
| CN (2) | CN115867319B (https=) |
| AU (1) | AU2021310171A1 (https=) |
| BR (1) | BR112022021179A2 (https=) |
| CA (1) | CA3179897A1 (https=) |
| IL (1) | IL297377A (https=) |
| WO (1) | WO2022012492A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114907353A (zh) * | 2021-02-09 | 2022-08-16 | 明慧医药（杭州）有限公司 | 一种前药化合物及其制备方法和用途 |
| CN117355527B (zh) * | 2021-07-20 | 2024-06-07 | 上海椿安生物医药科技有限公司 | 一种消炎偶联化合物药物及其制法和应用 |
| JP2025505812A (ja) * | 2022-02-21 | 2025-02-28 | オンクオリティ ファーマシューティカルズ チャイナ リミテッド | 化合物及びその用途 |
| KR20250012423A (ko) * | 2023-07-17 | 2025-01-24 | 차의과학대학교 산학협력단 | 금 나노입자 및 상환변환 나노입자로부터 형성된 일시적 광천공을 위한 나노복합체 |
| WO2026002095A1 (en) * | 2024-06-26 | 2026-01-02 | Coval Biopharma (Shanghai) Co., Ltd. | Drug delivery system for locally controlled release of therapeutic agents and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITPD20020271A1 (it) * | 2002-10-18 | 2004-04-19 | Fidia Farmaceutici | Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati. |
| EP1710257A4 (en) * | 2004-01-07 | 2011-03-23 | Seikagaku Kogyo Co Ltd | HYALURONIC ACID DERIVATIVE AND MEDICAMENT CONTAINING THEREOF |
| CA2609069A1 (en) * | 2005-05-18 | 2006-11-23 | Eurand Pharmaceuticals Limited | Antiproliferative conjugates comprising hyaluronic acid and n-derivatives of glutamic acid |
| IE20060049A1 (en) * | 2006-01-25 | 2007-08-08 | Eurand Pharmaceuticals Ltd | A novel drug delivery system: use of hyaluronic acid as a carrier moleclue for different classes of therapeutic active agents |
| IE20060565A1 (en) * | 2006-07-28 | 2008-02-06 | Eurand Pharmaceuticals Ltd | Drug delivery system based on regioselectively amidated hyaluronic acid |
| IE20070900A1 (en) * | 2007-12-12 | 2009-06-24 | Eurand Pharmaceuticals Ltd | New anticancer conjugates |
| BRPI0910570A2 (pt) * | 2008-04-22 | 2015-09-22 | Fidia Farmaceutici | uso de bioconjugados, e, formulações farmacêuticas |
| CN101745119B (zh) * | 2010-01-25 | 2012-07-25 | 中国药科大学 | 羧酸类药物-多糖偶联物及其制备方法与应用 |
| BR112014032916A2 (pt) * | 2012-06-28 | 2017-08-01 | Pfizer | anticorpos anti-fármacos e usos destes para o monitoramento de fármaco |
| WO2014038641A1 (ja) * | 2012-09-05 | 2014-03-13 | 中外製薬株式会社 | アミノ酸およびステリル基が導入されたヒアルロン酸誘導体 |
| KR101467076B1 (ko) * | 2013-02-20 | 2014-12-02 | 성균관대학교산학협력단 | 히알루론산-메토트렉세이트 접합체를 포함하는 관절염 예방 또는 치료용 약학적 조성물 및 이의 제조방법 |
| CN103751795B (zh) * | 2013-05-20 | 2017-02-08 | 中国药科大学 | 透明质酸‑抗肿瘤药偶联物及复合纳米粒组合物的制备和应用 |
| WO2015005458A1 (ja) * | 2013-07-10 | 2015-01-15 | 生化学工業株式会社 | グリコサミノグリカン誘導体及びその製造方法 |
| US9572832B2 (en) * | 2013-08-29 | 2017-02-21 | Holy Stone Healthcare Co., Ltd. | Compound of glycosaminoglycan and its fabrication method as well as application |
| CN104491875A (zh) * | 2014-12-22 | 2015-04-08 | 中国药科大学 | 一种基于透明质酸-难溶性药物前药的自聚纳米系统的制备方法 |
| CN107096036B (zh) * | 2017-04-12 | 2020-01-14 | 武汉理工大学 | 一种pH敏感型透明质酸-多柔比星纳米前药的制备方法及其应用 |
| JOP20190245A1 (ar) * | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| CN108467439A (zh) * | 2018-03-22 | 2018-08-31 | 盐城师范学院 | 一种水溶性紫杉醇抗癌药物的制备方法 |
| SG11202105128RA (en) * | 2018-12-12 | 2021-06-29 | Agency Science Tech & Res | Conjugates and nanoparticles of hyaluronic acid and epigallocatechin-3-o-gallate and uses thereof |
| CA3181304A1 (en) * | 2020-06-05 | 2021-12-09 | Abdel-Rahman Lawendy | Cannabinoid-hyaluronic acid bioconjugates |
-
2021
- 2021-07-13 CA CA3179897A patent/CA3179897A1/en active Pending
- 2021-07-13 KR KR1020227045471A patent/KR20230040957A/ko active Pending
- 2021-07-13 IL IL297377A patent/IL297377A/en unknown
- 2021-07-13 AU AU2021310171A patent/AU2021310171A1/en active Pending
- 2021-07-13 BR BR112022021179A patent/BR112022021179A2/pt unknown
- 2021-07-13 EP EP21841888.7A patent/EP4181963A4/en active Pending
- 2021-07-13 JP JP2022579760A patent/JP2023533679A/ja active Pending
- 2021-07-13 US US18/005,356 patent/US20230256106A1/en active Pending
- 2021-07-13 CN CN202180049488.5A patent/CN115867319B/zh active Active
- 2021-07-13 CN CN202311685488.1A patent/CN117838875B/zh active Active
- 2021-07-13 WO PCT/CN2021/105899 patent/WO2022012492A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230040957A (ko) | 2023-03-23 |
| CN117838875A (zh) | 2024-04-09 |
| EP4181963A1 (en) | 2023-05-24 |
| WO2022012492A1 (en) | 2022-01-20 |
| JP2023533679A (ja) | 2023-08-04 |
| IL297377A (en) | 2022-12-01 |
| CN115867319A (zh) | 2023-03-28 |
| CA3179897A1 (en) | 2022-01-20 |
| AU2021310171A1 (en) | 2022-11-10 |
| EP4181963A4 (en) | 2025-06-25 |
| US20230256106A1 (en) | 2023-08-17 |
| CN115867319B (zh) | 2024-01-02 |
| CN117838875B (zh) | 2025-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022021179A2 (pt) | Sistema de liberação de fármaco para a liberação local de agentes terapêuticos e usos do mesmo | |
| MX2025014988A (es) | Nuevas variantes de interleucina-2 para el tratamiento de cancer | |
| CR20210368A (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| EA201992484A1 (ru) | Системы доставки с замедленным высвобождением, содержащие бесследные линкеры | |
| CO2019013020A2 (es) | Anticuerpo anti-cdh6 y conjugado farmaco-anticuerpo anticdh6 | |
| MX2019003173A (es) | Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada. | |
| MX2022001541A (es) | Composiciones farmaceuticas y metodos para contrarrestar la cardiotoxicidad inducida por quimioterapia. | |
| BR112014016672A8 (pt) | compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo | |
| BR112019002730A2 (pt) | acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa | |
| BR112012032282A2 (pt) | administração transdérmica de memantina | |
| BR112015003836A2 (pt) | sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| MX2016008138A (es) | Sistema para el suministro transdermico de ingredientes activos. | |
| MX386251B (es) | Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson. | |
| MX2019011606A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
| BR112015004110A2 (pt) | sistemas e métodos de distribuição de drogas para tratamento de próstata | |
| MX2019013878A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
| BR112012030641B8 (pt) | Usos e composições para terapia farmacêutica oral | |
| IL307997A (en) | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases | |
| CL2022001636A1 (es) | Formulaciones inyectables de acción prolongada de sales de pamoato de ketamina | |
| BR112021023110A2 (pt) | Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton | |
| MX2019002121A (es) | Tratamiento conjunto para tratar el cancer de pancreas. | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| BR112016009749A8 (pt) | hidromorfona e naloxona para tratamento de dor e síndrome de disfunção intestinal opioide | |
| EP3769751A4 (en) | ULTRASONIC INDUCED DRUG DELIVERY SYSTEM WITH NANOBUBBLES DRUG CARRIER AND DRUG |